Advertisement

Angiogenesis

, Volume 8, Issue 4, pp 285–287 | Cite as

Antiangiogenesis: New frontiers in therapeutic development

  • Kenneth R. LaMontagne
Meeting report

Keywords

Vascular Endothelial Growth Factor SU5416 Tumor Endothelial Cell Ferumoxide Vascular Endothelial Growth Factor Trap 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marler JJ, Fishman SJ, Kilroy SM et al (2005) Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116: 38–45PubMedCrossRefGoogle Scholar
  2. 2.
    Dowlati A, Robertson K, Radivoyevitch T et al (2005) Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 11: 7938–44PubMedCrossRefGoogle Scholar
  3. 3.
    Hida K, and Klagsbrun M (2005) A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65: 2507–10PubMedCrossRefGoogle Scholar
  4. 4.
    Peng SB, Yan L, Xia X et al (2005) Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 22: 2293–304CrossRefGoogle Scholar
  5. 5.
    LaMontagne K, Littlewood-Evans A, Schnell C et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res (In press)Google Scholar
  6. 6.
    Glade Bender J, Cooney EM, Kandel JJ, and Yamashiro DJ (2004) Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7: 289–300PubMedCrossRefGoogle Scholar
  7. 7.
    Peters BA, Diaz LA, Polyak K et al (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11: 261–2PubMedCrossRefGoogle Scholar
  8. 8.
    Carano RA, Ross AL, Ross J et al (2004) Quantification of tumor tissue populations by multispectral analysis. Magn Reon Med 51: 542–51CrossRefGoogle Scholar
  9. 9.
    Drevs J, Konerding MA, Wolloscheck T et al (2004) The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7: 347–54PubMedCrossRefGoogle Scholar
  10. 10.
    Shukeir N, Garde S, Wu JJ et al. (2005) Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs 16: 1045–51PubMedCrossRefGoogle Scholar
  11. 11.
    Khanna C and Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 26: 513–23PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Cancer Therapeutics, Johnson & Johnson Pharmaceutical Research & DevelopmentRaritanUSA
  2. 2.Cancer Therapeutics, Johnson & Johnson Pharmaceutical Research & DevelopmentRaritanUSA

Personalised recommendations